Clinical trials in Bad Oeynhausen – page 9

329 clinical trials in Bad Oeynhausen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Bad Oeynhausen at a glance

329

clinical trials

Research sites1

Quick filters

329 trials in Bad Oeynhausen

Open in trial search

Gastric cancer+3

Recruiting

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Shanghai Henlius Biotech Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Diabetic neuropathy

Recruiting

Study on the Effectiveness and Safety of VX-993 and Pregabalin for Pain Relief in Patients with Diabetic Peripheral Neuropathy

Registered drug

Study on the Effectiveness and Safety of VX-993 and Pregabalin for Pain Relief in Patients with Diabetic Peripheral Neuropathy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Pregabalin
Sponsor:Vertex Pharmaceuticals Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Basal cell carcinoma

Recruiting

Evaluation of Cemiplimab Safety and Effectiveness as First Treatment for Advanced Basal Cell Carcinoma in Adult Patients

Registered drugNo placebo

Evaluation of Cemiplimab Safety and Effectiveness as First Treatment for Advanced Basal Cell Carcinoma in Adult Patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Non-small cell lung cancer stage III+2

Recruiting

Study of durvalumab with chemotherapy (paclitaxel, cisplatin, carboplatin, vinorelbine) in patients with stage IIIA/B non-small cell lung cancer that can be removed by surgery

Registered drugNo placebo

Study of durvalumab with chemotherapy (paclitaxel, cisplatin, carboplatin, vinorelbine) in patients with stage IIIA/B non-small cell lung cancer that can be removed by surgery

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Contact Research Centre

Study on the Long-Term Safety of Belimumab for Adults with Systemic Sclerosis-Related Lung Disease

Recruiting

Registered drugNo placebo

Study on the Long-Term Safety of Belimumab for Adults with Systemic Sclerosis-Related Lung Disease

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Belimumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Malignant peritoneal neoplasm+2

Recruiting

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AGO Research GmbH

Contact Research Centre

Colon cancer stage III+1

Recruiting

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Neonatal respiratory distress syndrome

Recruiting

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Poractant Alfa
Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Contact Research Centre

Diffuse large B-cell lymphoma

Recruiting

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo

Germany

Participants:65+ years
Substances:Busulfan
Sponsor:Medical Center - University Of Freiburg

Contact Research Centre

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Topotecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Bad Oeynhausen

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials exploring treatments for heart failure and cardiovascular disease, including studies of novel compounds like baxdrostat and pelacarsen to reduce major cardiovascular events.

Heart Failure Prevention
Coronary Artery Disease
Cardiomyopathy Management

Advanced diagnostic approaches including PET imaging for coronary conditions.

02 Metabolic Disorders

Comprehensive research focusing on Type 2 Diabetes management and its complications, including studies on innovative treatments for diabetic peripheral neuropathy.

Diabetes Management
Cholesterol Control
Obesity Treatment

Novel therapeutic approaches for hypercholesterolemia and weight management.

03 Renal Studies

Ground-breaking research in chronic kidney disease treatment, particularly focusing on complications associated with diabetes and hypertension.

Acute Kidney Injury
Chronic Kidney Disease
Renal Protection

Innovative therapies targeting kidney function preservation and disease progression.

04 Specialized Cardiac Care

Advanced research in hypertrophic cardiomyopathy and cardiac structural conditions, including maternal-fetal cardiac development studies.

Atrial Fibrillation
Acute Myocardial Infarction
Congenital Heart Conditions

Targeted therapies for specific cardiac conditions and preventive interventions.

Back to Germany All countries

Clinical trials in Bad Oeynhausen – page 9

329 trials in Bad Oeynhausen

Gastric cancer+3

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Acute myeloid leukaemia

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Diabetic neuropathy

Study on the Effectiveness and Safety of VX-993 and Pregabalin for Pain Relief in Patients with Diabetic Peripheral Neuropathy

Acute myeloid leukaemia

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Basal cell carcinoma

Evaluation of Cemiplimab Safety and Effectiveness as First Treatment for Advanced Basal Cell Carcinoma in Adult Patients

Non-small cell lung cancer stage III+2

Study of durvalumab with chemotherapy (paclitaxel, cisplatin, carboplatin, vinorelbine) in patients with stage IIIA/B non-small cell lung cancer that can be removed by surgery

Study on the Long-Term Safety of Belimumab for Adults with Systemic Sclerosis-Related Lung Disease

Study on the Long-Term Safety of Belimumab for Adults with Systemic Sclerosis-Related Lung Disease

Malignant peritoneal neoplasm+2

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Colon cancer stage III+1

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Neonatal respiratory distress syndrome

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Diffuse large B-cell lymphoma

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Small cell lung cancer

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Filter the trials

Other cities in Germany

Clinical research in Bad Oeynhausen

Prefer not to search on your own, or looking for clinical trials for a rare disease?